The FDA could use its regulatory discretion to increase its scrutiny of laboratory-developed diagnostics, including those that are tools for personalized medicine, FDA Commissioner Dr. Margaret Hamburg said at a conference. Tests developed and offered by labs are becoming more complex, and the FDA wants to ensure that "the accuracy and clinical validity of high-risk tests are established before they come to market," she said.

Full Story:

Related Summaries